Target
ASXL1
9 abstracts
Abstract
Refining risk stratification in CMML: A comprehensive assessment of the IPSS-M and other molecularly informed models.Org: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL,
Abstract
Clonal hematopoiesis (CH) associated mutations in patients with advanced solid tumors enrolled in phase I clinical trials.Org: Gustave Roussy Cancer Campus, Gustave Roussy Département d'Organisation du Parcours Patient, Paris Saclay University, Department of Biostatistics and Epidemiology, Department of Medical Biology and Pathology, Gustave Roussy, France, Paris,
Abstract
Clonal hematopoiesis in survivors of childhood cancer.Org: New York City, St Louis, Washington University School of Medicine, ModernaTX, St. Louis,
Abstract
Outcomes of individuals with clonal hematopoiesis evaluated at a cancer center.Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Hematopathology, Beijing Friendship Hospital, Capital Medical University,
Abstract
A step toward genomic equity: Mutational profiling of patients with myeloid neoplasm in the largest minority-serving hospital in metropolitan Chicago.Org: John H. Stroger, Jr. Hospital of Cook County, Chicago, IL,
Abstract
Superior outcomes after allogeneic stem cell transplantation (SCT) among patients (Pts) ≥ 60 years (yrs) treated with cladribine (CLAD), low dose cytarabine (LDAC) plus venetoclax (Ven) for newly diagnosed acute myeloid leukemia (AML).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation & Cellular Therapy,
Abstract
Co-mutation of ATM and ASXL1 and relationship to durable response of a novel PARP1/2 inhibitor, venadaparib, in patients with pancreatic cancer.Org: Idience, Idience Inc.,
Abstract
The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine.Org: VCU School of Medicine, VCU Massey Cancer Center, VCU Department of Internal Medicine, Virginia Commonwealth University School of Medicine, VCU Department of Biostatistics,
Abstract
Clinical outcomes of core binding factor acute myeloid leukemia in the modern era.Org: Virginia Commonwealth University School of Medicine, VCU Massey Cancer Center, VCU School of Medicine, VCU Department of Internal Medicine, VCU Department of Biostatistics,